The markers to predict the response to neoadjuvant therapy in patients with rectal cancer

Locally advanced rectal cancer is currently treated with preoperative radiochemotherapy, but the response is not uniform. Most patients benefit from preoperative CRT, however, a small proportion of a patient population is less likely to respond to the treatment. The purpose of this study was to measure neoadjuvant therapy combined with Ki-67 and VEGF expression in pretreatment biopsies and postoperative specimens，serum carcinoembryonic antigen (CEA) and CA19-9 level from patients with locally advanced rectal cancer receiving intensive neoadjuvant treatment and to correlate the findings with clinical outcome.